

# **Ginsan Improved Thl Immune Response Inhibited by Gamma Radiation**

## Seon-Kyu Han<sup>1,2</sup>, Jie-Young Song<sup>1</sup>, Yeon-Sook Yun<sup>1</sup>, and Seh-Yoon Yi<sup>3,4</sup>

*1Laboratory of Immunology, Korea Institute of Radiological and Medical sciences 215-4 Gongneung-dong, Nowonku, Seoul 139-706, Korea, 2Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology, Seoul 130-650 Korea, 3Technical Research Institute, Microbia Corp. Suwon 445-743, Korea, and 4College of Natural Science, Suwon University. Suwon 445-743, Korea* 

*(Received July 27, 2004)* 

Gamma radiation causes suppression of the immune function, and immune properties are related to cytokine production. In the present study, the polysaccharide, Ginsan, purified from an ethanol-insoluble fraction of Ginseng (Panax ginseng C.A. Meyer, Araliaceae) water extract was studied to assess its effects on the immunosuppressive activities of gamma radiation. Ginsan was found to stimulate murine normal splenocytes by inducing the mRNA expressions of Thl and Th2 type cytokines, and also restore the mRNA expression of IFN-y, Thl cytokine, after its inhibition by whole-body gamma irradiation. Therefore, Ginsan was found to restore the T lymphocytes function that had been suppressed by gamma irradiation in allogenic MLR (mixed lymphocyte reactions). However, Ginsan exhibited no excessive stimulatory effects on the control group. The above results indicated that Ginsan may constitute a new noble agent for the improvement of gamma radiation-induced immunosuppression.

**Key words:** Ginsan, Gamma radiation, Cytokines

# **INTRODUCTION**

Recently, the discovery of new noble agents has been extensively pursued in order to find a way to reduce the deleterious side effects of radiation. Many cytokines, in particular, have been purified, characterized, cloned and synthesized. Recombinant cytokines are well known for their function as immune modulators (Geimm *et aL,* 1982; Mule *et aL,* 1985; Rosenberg *et aL,* 1985; Tang *et aL,*  1986; Ballas *et aL,* 1987; Ochoa *et aL,* 1987), and have been used in immunotherapy for a vast variety of cancers, but tend to be too toxic, with very short half lives, suggesting that their endogenous induction may prove a more effective immunotherapeutic approach in the treatment of cancer. Therefore, immune modulators able to induce and prolong the secretion of various endogenous cytokines are expected to be quite useful in prevention and treatment of cancer (Oldham 1982; Talmadge *et aL,* 1984; Smalley and OIdham 1986;

Correspondence to: Seh-Yoon Yi, Laboratory of Immunology, Institute of Radiological and Medical Sciences, 215-4 Gongneungdong, Nowon-ku, Seoul 139-706, Korea Tel: 82-31-222-7421, Fax: 82-31-222-7423 E-mail: syyi0820@ empal.com.

Talmadge and Herberman 1986; Wimer 1989). Indeed, biological response modifiers (BRM), including bacillus calmette-Guerin (BCG) (Yanagawa *et al.,* 1979), OK-432 (Uchida and Micksche 1981), IFN (Murren and Buzaid 1989, Strander 1989), AS101 (Sredi *et al.,* 1987), lentinan (Maeda *et al.,* 1984) and flavonoids (Wilrout and Hornung 1988) have been identified as nontoxic immune modulators and shown to act as effectors or mediators of effective immune responses in cancer prevention and therapy.

Ginseng *(Panax ginseng* C.A. Meyer, *Araliaceae)* has been studied for a very long time. Its anticancer activities appear to be due to the direct cytotoxic effects of low molecular-weight poly-acetylene compounds (Kim *et al.,*  1989) and the immune modulating activity of high molecular-weight compounds (Singh *et al.,* 1983, Gao *et aL,* 1989, Kim *et aL,* 1990). It has been reported that ginseng polysaccharides can induce natural killer (NK) cell activity, lymphocyte proliferation and macrophage activation. Therefore, in a previous study, we purified and characterized polysaccharide Ginsan from old white Ginseng, and found Ginsan to be an excellent radioprotective agent, as well as an ideal BRM. Ginsan was demonstrated to induce the proliferation of normal

splenocytes and a number of GM-CFU in normal bone marrow cells, both *in vitro* and *in vivo.* Ginsan also improved various hematopoietic parameters, including bone marrow and spleen cellularity, GM-CFU content and CFU-S levels in bone marrow (Song *et al.,* 2003).

The immunosuppressive effect of gamma radiation is well known. Different levels of radiosensitivity have been reported among lymphocyte subpopulations; for example, Thl cells are more radiosensitive than Th2 cells (Galdiero *et aL,* 1994). We recently reported that gamma radiation inhibited the mRNA expression of IFN- $\gamma$ , a Th1 cytokine, as well as related transcription factors, while Th2 cytokine and proinflammatory cytokine expressions were rapidly induced on exposure to gamma radiation. The gammainduced inhibition of Thl cytokine mRNA expression also effected a reduction in the functional activity of T lymphocytes (Han *et aL,* 2002), which resulted from the effects of gamma radiation, rather than indicating differential radiosensitivities among lymphocyte subpopulations. In order to improve these immunosuppressive effects of gamma radiation, in this study, a new noble agent, Ginsan, was investigated for its effect on the mRNA expression of cytokines in murine splenocytes *in vitro* and *in vivo,* as well as the functional activity of the T lymphocytes, using allogenic MLR. Ginsan was found to be a good candidate for the alleviation of gamma radiation-induced immunosuppression.

# **MATERIALS AND METHODS**

#### **Animals**

Seven or eight-week old Balb/c and C57BL/6 mice were maintained in an accredited Laboratory Animal Care facility operated by the Korea Cancer Center Hospital (KCCH). We used 2-4 mice per group in every sample preparation. All mice used, weighing  $20±2$  g each and were supplied with solid feed and water. The temperature of the laboratory in which the animals were maintained was  $22 \pm 2^{\circ}$ C, with a humidity of 55~60%.

#### **Preparation of Ginsan**

Polysaccharide 'Ginsan' was purified from an ethanolinsoluble fraction of a *Panax ginseng* water extract, as described previously (Yun *et aL,* 1993). Further purification was performed by Sephacryl S-500 gel column chromatography (2.6x100 cm), with 0.1 M sodium phosphate buffer (pH 7.4) and by DEAE-Sephadex A50 column chromatography (3x30 cm), with a 0 to 1 M linear gradient of NaCl. The Ginsan was composed of  $\alpha$  (1- $\rightarrow$ 6) glucopyranoside and  $\beta$  (2 $\rightarrow$ 6) fructofuranoside, with a molar ratio of 3:7, and average molecular weight of 2,000 Kd (Data are in press). The lot containing high LAK activity and splenocyte proliferation was used in the following experiments.

#### **Cell culture**

The spleens were removed from the mice by sectioning with sterilized scissor. The extracted spleens were transferred to fresh RPMI 1640 medium, containing  $2\times10^{-2}$  M HEPES,  $2\times10^{-3}$  M glutamine,  $1\times10^{-3}$  M pyruvate, 100 U/mL penicillin, 50  $\mu$ g/mL streptomycin, 5×10<sup>-5</sup> M 2-mercaptoethanol and 1% non-essential amino acids, supplemented with 5% fetal bovine serum (FBS) (Life Technologies, Cergy-Pontoise, France), and then rinsed. The spleens were then pressed and chopped gently with the tail of a 1 mL syringe. The cell suspension was filtered through sterilized gauze in order to remove cell debris, washed with fresh RPMI 1640 medium and the cells counted using the trypan blue exclusion method. The isolated splenocytes were cultured in RPMI 1640 medium and treated with Ginsan (50  $\mu$ g/mL) for 3, 6 and 24 h. The Ginsan (100 mg/kg) solutions were injected intraperitoneally (i.p.) into mice 24 h prior to whole-body irradiation. The concentration of Ginsan was determined in our previous report (Song *et aL,* 2003). The irradiated mice were maintained in the animal care laboratory of the KCCH for a further 5 days, and then sacrificed. The splenocytes were isolated from the mice and cultured in RPMI 1640.

#### **Gamma irradiation**

The splenocytes were irradiated with 5 Gy of  $\gamma$ -radiation, and the mice with 4.5 Gy, at a dose rate of 97.1 cGy/min, using a <sup>60</sup>Co theraton-780 (Atomic Energy of Canada, Ltd., Canada).

#### **RNA preparation**

Total RNA was extracted as follows. After appropriate treatments and incubation, the cells were collected and disrupted with RNAzol (Tel-Test, Inc. Texas, USA). Fifty microliters of chloroform were added and the mixture vortexed and incubated on ice for 10 minutes. The mixture was centrifuged at 12,000 rpm for 15 minutes at 4°C, and the upper layer transferred to a new chilled tube. An equal volume of chilled isopropanol was added to the upper layer, and incubated for 1 h at -20°C. After 20 minutes of centrifugation at 12,000 rpm at  $4^{\circ}$ C, the RNA pellets were collected and washed with chilled 75% ethanol. The RNA pellets were completely dried at room temperature, and dissolved in diethyl pyrocarbonate (DEPC)-treated distilled water. The RNA concentrations were determined spectrophotometrically at a wavelength of 260 nm.

## **Semi-quantitative reverse transcriptase (RT)-polymerase chain reaction (PCR)**

One microgram of intact total RNA was reversibly

transcribed into first-strand cDNA, and the transcribed cDNA amplified using a polymerase chain reaction (PCR), as follows. A final volume of 20 uL reverse transcriptase (RT) reaction mixture contained: 50 mM Tris-HCI (pH 8.3), 3 mM MgCl<sub>2</sub>, 75 mM KCl, 2.5  $\mu$ g/mL pd(N)<sub>6</sub> primer (random hexamer), deoxyribonucleoside tri-phosphate (dNTP) mixture (0.5 mM each of 2' deoxyadenosine 5'-triphosphate (dATP), 2' deoxyguanosine 5'-triphosphate (dGTP), 2' deoxythymidine 5'-triphosphate (dTTP), 2' deoxycytosine 5'-triphosphate (dCTP) and 10 U of AMV-reverse transcriptase (RT). The RT reaction was performed at 60°C for 1 minute, 37°C for 90 minutes and at 95°C for 1 minute, and the synthesized cDNA then cooled on ice. The reaction mixture for PCR contained: 10 µL cDNA template from the RT reaction, 10 mM Tris-HCI (pH 8.3), 50 mM KCI, 1.5 mM MgCI<sub>2</sub>, dNTP mixture (0.5 mM each of dATP, dGTP, dTTP and dCTP),  $1.0 \mu M$  of each primer and 0.5U Taq DNA polymerase. The oligonucleotide primers used in these experiments are listed in Table I. PCR was performed with a DNA thermal cycler (Hybaid, United Kingdom) at  $94^{\circ}$ C for 1 minute, at  $55-60^{\circ}$ C for 1 minute and at 72°C for 1 minute per cycle. The amplified products were visualized by electrophoresis on a 1% agarose gel in the presence of  $0.5 \mu g/mL$  ethidium bromide (EtBr). B-Actin primers were used as an internal control in all cases.

#### **RNase protection assay (RPA)**

The Ginsan (100 mg/kg) was administered to mice 24 h prior to irradiation, and the mice kept alive for a further 5 days. Subsequently, the total RNA was isolated from the splenocytes, and frozen at -70°C until used. RT-PCR, as described above, and RPA were performed. A cytokine RNA probe, with a maximum yield of  $3\times10^6$  Cherenkov counts/pL, was synthesized *via* multi-probe DNA templates, following the manufacturer's instructions (Pharmingen Co.). The total RNA (10 or 20 mg) in DEPC-treated distilled water was frozen for 15 minutes at -70°C, and then dried completely in a vacuum evaporator centrifuge without heating. The hybridization was then performed according to the manufacturer's instructions. The hybridized RNA samples were digested with 100  $\mu$ L of RNase cocktail for 45 minutes at 30°C, and then purified. Ammonium acetate  $(4M, 120 \mu L)$  and 650  $\mu L$  ice-cold 100% ethanol were added, and then precipitated at -70°C. The dried pellets were dissolved in 5  $\mu$ L of 1X loading buffer, heated for 3 minutes at  $90^{\circ}$ C, and then cooled immediately prior to loading the samples onto the gel. A set of gel plates were cleaned with chloroform (CHCI3) or DEPC treated water, and the gel mold (0.4 mm spacers) then carefully assembled. The glass plates were wiped with 70% ethanol and coated with SIGMACOAT. Five-percent acrylamide gel (19:1 acrylamide/bis) electrophoresis was then performed.

**Table** I. Oligonucleotides used in the RT-PCR

oligonucleotides		Sequence	Expected size
IFN- $\gamma$	5'-primer	5'-TACTGCCACGGCACAGTCATTGAA-3'	405
	3'-primer	5'-GCAGCGACTCCTTTTCCGCTTCCT-3'	
$IL-2$	5'-primer	5'-GTCAACAGCGCACCCACTTCAAGC-3'	451
	3'-primer	5'-GCTTGTTGAGATGATGCTTTGACA-3'	
IL-12 (p35)	5'-primer	5'-ACCTCAGTTTGGCCAGGGTC-3'	500
	3'-primer	5'-GTCACGACGCGGGTGGTGAAG-3'	
$IL-4$	5'-primer	5'-ACGGAGATGGATGTGCCAAACGTC-3'	279
	3'-primer	5'-CGAGTAATCCATTTGCATGATGC-3'	
$IL-5$	5'-primer	5'-ATGACTGTGCCTCTGTGCCTGGAGC-3'	243
	3'-primer	5'-CTGTTTTTCCTGGAGTAAACTGGGG-3'	
$IL-10$	5'-primer	5'-AGACTTTCTTTCAAACAAAGGACCAGCTGGA-3'	
	3'-primer	5'-CCTGGAGTCCAGCAGACTCAATACACACTGC-3'	421
$IL-1\beta$	5'-primer	5'-TGAAGGGCTGCTTCCAAACCTTTGACC-3'	361
	3'-primer	5'-TGTCCATTGAGGTGGAGAGCTTTCAGC-3'	
TNF- $\alpha$	5'-primer	5'-GCGACGTGGAACTGGCAGAAG-3'	340
	3'-primer	5'-TCCATGCCGTTGGCCAGGAGG-3'	
<b>GM-CSF</b>	5'-primer	5'-CCCATCACTGTCACCCGGCCTTGG-3'	279
	3'-primer	5'-GTCCGTTTCCGGAGTTGGGGGGC-3	
β-actin	5'-primer	5'-TGGAATCCTGTGGCATCCATGAAAC-3'	349
	3'-primer	5'-TAAAACGCAGCTCAGTAACAGTCCG-3'	

## **Allogenic mixed lymphocyte reaction** (MLR)

Six-week-old Balb/c mice  $(H-2<sup>d</sup>)$  were treated with Ginsan (100 mg/kg) 24 h, or left untreated prior to the gamma-irradiation at a dose of 4.5 Gy. After 5 days, the mice were sacrificed, the splenocytes collected from each group, and used as responder cells. Concomitantly, the splenocytes from the C57BL/6 mice  $(H-2<sup>b</sup>)$  were irradiated with a dose of 20 Gy, and used as stimulator cells. Responder cells  $(5\times10^6 \text{ cells/mL})$  were cultured in RPMI 1640, supplemented with 5% (v/v) fetal bovine serum (FBS),  $2\times10^{-2}$  M HEPES buffer,  $2\times10^{-3}$  M glutamine,  $1\times10^{-3}$ M sodium pyruvate, 100 U/mL penicillin, 50  $\mu$ g/mL streptomycin,  $5\times10^{-5}$  M 2-mercaptoethanol and 1% non-essential amino acids, together with stimulator cells  $(5\times10^6 \text{ cells})$ mL), on flat-bottomed 96-well microplates, for 4 days at 37 $^{\circ}$ C, in an atmosphere of 5%  $CO<sub>2</sub>$ . Each experiment was performed in triplicate. The control contained only responder cells.  ${}^{3}$ [H]-Thymidine (2 mCi/well) was added to each well 24 h prior to harvesting, and the amount of  ${}^{3}$ [H]thymidine incorporated determined using a B-counter (Tri-Carb 4530, Packard Co.).

# **RESULTS**

### **Ginsan induced the mRNA expression of cytokines** *in vitro*

In order to assess the effects of Ginsan on cytokine gene regulation *in vitro,* the spienocytes isolated from Balb/c mice were cultured for 3, 6 or 24 h, either in the presence or absence of 50  $\mu$ g/mL Ginsan. RT-PCR was performed on the total extracted RNA to determine the mRNA levels of Th1 type, Th2 type and proinflammatory cytokines. As shown in Fig 1, IFN- $\gamma$  was induced after 6 h, but reduced 24 h after Ginsan treatment. Conversely, the



Fig. 1. Effects of Ginsan on mRNA expressions of Thl type cytokines *in vitro.* RT-PCR was performed with total RNA isolated from untreated cells (control), and cells cultured for the indicated times in the presence of Ginsan (50 μg/mL). One microgram of intact total RNA was reversibly transcribed into first strand cDNA, and amplified using a polymerase chain reaction (PCR). The PCR products were analyzed by 1% agarose gel electrophoresis. The data shown represents one of two independent experiments.

mRNA level of IL-2 was highly induced at 24 h, whereas that of IL-12 was found to be significantly elevated at all times. Th2 type cytokines, such as IL-4, IL-5 and IL-10, were rapidly induced within 3 h, and persisted for 6 or 24 h in the presence of Ginsan. The IL-5 levels were increased at 6 hours, and persisted until the 24 h measurement (Fig. 2). mRNA expression of the proinflammatory cytokines also increased very rapidly, and persisted until the 24 h measurement (Fig. 3). The above results strongly indicated that Ginsan was able to activate the immune cells through the induction of endogenous cytokine expression.

## **Ginsan prevented the inhibition of IFN-y mRNA expression by gamma irradiation** *in vivo*

Ginsan solution or PBS (control) was injected intraperitoneally *(Lp.)* into groups of three or four mice, 24 h prior to gamma irradiation. Five days after irradiation, the



Fig. 2. Effects of Ginsan on mRNA expression of Th2 type cytokines *in vitro.* RT-PCR was performed with total RNA isolated from untreated cells (control), and cells cultured for the indicated times in the presence of Ginsan (50 µg/mL). Isolation of total RNA, its transcription into cDNA and amplification by PCR were carried out, as described in the legend to Fig. 1 and the methods section.



Fig. 3. Effects of Ginsan on mRNA expression of proinflammatory cytokines *in vitro.* RT-PCR was performed with total RNA from untreated cells (control), and cells cultured for the indicated times in the presence of Ginsan (50  $\mu$ g/mL). Isolation of total RNA, its transcription into cDNA and amplification by PCR were carried out, as described in the legend to Fig. 1 and the methods section.

splenocytes were isolated, the total RNA purified, and RT-PCR and RPA performed, as described above. We confirmed our previous, recently-reported RT-PCR data (Song *et al.*, 2003). The IFN-y levels were reduced as a result of irradiation, but recovered upon Ginsan treatment (Fig. 4). We performed RNase protection assays (RPA) to verify these effects of Ginsan on the cytokine regulation *in vivo.* As shown in Fig. 5, we also observed gamma



Fig. 4. Effects of Ginsan on cytokine expression examined by RT-PCR. Ginsan (100 mg/kg) and PBS solution were injected intraperitoneally (i.p.) into mice 24 h prior to whole-body gamma irradiation (Ct: control group, IR: irradiated group, IR+Gs: treated with Ginsan and irradiated group). Five days after irradiation, the mice were sacrificed, the splenocytes isolated and the total RNA extracted from each group. RT-PCR was performed as described in the legend to Fig. 1 and the methods section.



Fig. 5. Effects of Ginsan on cytokine expression examined by RNase protection assay (RPA). Ginsan (100 mg/kg) and PBS solutions were injected intraperitoneally (i.p.) into mice 24 h prior to whole-body gamma irradiation (Ct: control group, IR: irradiated group, IR+Gs: treated with Ginsan and irradiated group). Five days after irradiation, the mice were sacrificed and the splenocytes isolated from each group. The total RNA (10~20 µg) extracted from each group was hybridized with a synthesized RNA probe, and the hybridized RNA digested with RNase. Digested samples were analyzed by 5% acrylamide gel (19:1 acrylamide/bis) electrophoresis (Lane 1; undigested probe used as marker, lane 2; control RNA supplied from Pharmingen).

radiation-induced reductions in the levels of IL-4, IL-10 and IFN-y cytokine expressions. The protection of the IFN- $\gamma$  levels due to Ginsan treatment was detected, but IL-4 and IL-10 appeared not to be protected by Ginsan. The results of RPA were consistent with our RT-PCR data. Interestingly, IL-15, which is involved in proliferation and cytokine production in T cells, was detected, and slightly increased as a result of Ginsan treatment. The above results indicated that Ginsan was able, *in vivo,* to reverse or mitigate the gamma-induced reduction in the levels of Thl cytokines.

## **Ginsan protected the functional activity of T lymphocytes inhibited by gamma irradiation**

The gamma radiation-induced reduction of Thl type cytokines can result in the inhibition of Thl immune responses, as the reduction of Thl type cytokines affects the differentiation of Thl cells. In order to evaluate the functional consequences of T-lymphocytes by gamma irradiation and the treatment with Ginsan, allogenic MLR was performed, as described in the Methods section. Thus, Ginsan (100 mg/kg) was injected intraperitoneally (i.p.) into mice 24 hours prior to gamma irradiation, and the splenocytes isolated from each group (Balb/c; H-2<sup>d</sup>), 5 days later, for use as responder cells. They were cultured for 4 days, with prepared stimulators  $(C57BL/6; H2<sup>b</sup>)$  at a



Fig. 6. Effects of gamma irradiation and Ginsan on the functional activity of T lymphocytes. Ginsan (100 mg/mL) and PBS solutions were injected intraperitoneally (i.p.) into mice 24 h prior to whole-body gamma irradiation (Ct: control group, IR: irradiated group, Gs: group treated with Ginsan, Gs+IR: group treated with Ginsan and irradiated). Five days after irradiation, the mice of each group were sacrificed and the splenocytes isolated. The splenocytes of each group were used as responder cells (Balb/c:  $H-2<sup>d</sup>$ ) and cultured in the presence of prepared stimulator cells  $(C57BL/6$ : H-2<sup>b</sup>), which had been irradiated with 20 Gy, at a ratio of 1:1 (responder: stimulator), in flat-bottomed 96-well microplates for 4 days.  ${}^{3}$ [H]-thymidine (2  $\mu$ Ci/well) was added to each well 24 h prior to harvesting, and the amount of  ${}^{3}$ [H]-thymidine incorporated measured by a  $\beta$ -counter. This experiment was carried out in triplicate from three different preparations. The values are presented as the mean  $\pm$  SE.

1:1 ratio (responder: stimulator), in flat-bottomed 96-well microplates. As shown in Fig. 6, Ginsan (Gs) did not induce excess activity in the control group (Ct), indicating that Ginsan might be a good candidate as an immune modulator. While the activity of the irradiated group (IR) was 20-22% that of the control group (Ct), the activity of the treated group (Gs  $+$  IR) recovered to a level 40% that of the control group. This represents a 2-fotd increase compared with the activity of the T cells in the irradiated group (IR). Based on the recovery of Thl cytokines, Ginsan treatment can safely be said to have improved the effective function of the T cells.

# **DISCUSSION**

It is well established that gamma radiation causes immunosuppression and inflammation. We recently reported that gamma radiation induced immunosuppression by inhibiting the mRNA expression of Th1 type cytokines and related transcription factors. We also determined that gamma radiation interfered with STAT1, which is involved in the IFN-y signaling pathway (Han *et al.*, 2002). Therefore, we have been searching for new agents that can improve the gamma radiation-induced reduction of Thl type cytokines. Indeed, new noble agents are currently being actively sought by many researchers, in the hope of finding a way to reduce the deleterious side effects of radiation. The induction of endogenous cytokines appears to be a more promising approach to cancer immunotherapy than recombinant cytokines. Therefore, biological response modifiers (BRM) are used as nontoxic immune modulators, effectors or mediators of an effective immune response in the field of cancer prevention and therapy.

We selected Ginsan, a polysaccharide extracted from *Ginseng Radix Alba,* as a likely candidate for the relief of the immunosuppressive effects of gamma irradiation. The radioprotective and immune modulating effects of Ginsan were recently demonstrated in our laboratory (Song *et aL,*  2003): Ginsan effectively improved various reduced hematopoietic parameters, including bone marrow and spleen cellularity, which had been compromised by gamma radiation. In the present study, we demonstrated that Ginsan induced the production of Thl, Th2 and proinflammatory cytokines in normal splenocytes *in vitro*  (Fig. 1-3), further confirming our previous results, which showed that Ginsan was a mitogen of T lymphocytes (Lee *et al.,* 1997).

In order to assess the *in vivo* effects of Ginsan on cytokine production after gamma irradiation, we administered Ginsan to mice 24 h before whole-body gamma irradiation. The duration of administration is very important; therefore, we previously established the optimal conditions for the administration of Ginsan. For examination of the cytokine profiles, the mice were sacrificed 5 days after irradiation, when the spleen cell number had begun to recover (Song *et aL,* 2003). Although a reduction in the levels of Thl and Th2 type cytokines was observed 5 days post-irradiation, Ginsan mainly induced the expression of Th1 type cytokines, such as IFN- $\gamma$ , in both RT-PCR and RPA data (Figs. 4, 5). Conversely, the levels of IL-4 and IL-10, both Th2 type cytokines, were found to have only slightly increased above those in the radiation/Ginsan group, and were not comparable to the RPA data of the control group. Moreover, IL-4 was not induced by Ginsan treatment, according to our RT-PCR data, but Ginsan clearly stimulated IFN-y mRNA expression.

As the generation of cytotoxic T lymphocytes (CTL) by Th1 type cytokines, such as  $IFN-\gamma$  and IL-12, is crucial in a host's response to tumors, transplants and viruses, and is particularly related to the mixed lymphocyte reaction (MLR), allogenic MLR was performed. As shown in Fig. 5, Ginsan-mediated protection of the Thl type cytokine expression resulted in an improvement in the functional activity of the T lymphocytes. Gamma irradiation is known to significantly inhibit the proliferation of effective T cells by reducing the levels of Thl type cytokines. However, Ginsan treatment prior to irradiation prevented this gamma radiation-induced effect, *via* the induction of endogenous cytokine gene expression. Interestingly, IL-15, which is associated with proliferation and cytokine-mediated T cell production, was detected in our RPA data, indicating that Ginsan has a slight inductive effect on IL-15 (Fig. 5). IL-15 exhibits similar activity with IL-2, possibly due to its interaction with IL-2 receptors. However, it is becoming evident that IL-15 and IL-2 differentially exert their effects on a number of cell types, and are thus expected to play distinct roles *in vivo* (Shuat *et aL,* 1994). It has recently been reported that IL-15 increases the activity of cytotoxic T lymphocytes (Khan and Casciotti 2000; Chen *et aL,*  2000). Therefore, increased IL-15 and IFN- $\gamma$  mRNA expressions, due to Ginsan treatment, are expected to contribute to improvements in the gamma radiation-inhibited functional activity of T lymphocytes. Although Ginsan induced mRNA expressions of all cytokine types in normal splenocytes *in vitro,* allogenic MLR revealed no excessive stimulatory effects of Ginsan in the Ginsan-treated control group (G). If Ginsan excessively activates the normal immune system, it would be practically unsuitable in its application as an immune modulator. Furthermore, Ginsan enhanced the effective functional activity of the T lymphocytes, about 2 folds that in the irradiated group without Ginsan (IR) (Fig. 6), thus indicating that Ginsan effectively alleviates the gamma radiation-induced inhibition of Thl type cytokine expression, and improves the gammainduced inhibition of the Thl immune response.

In summary, Ginsan may constitute a potent stimulator,

as it clearly stimulates the endogenous mRNA expression of cytokines. IFN-y and Thl type cytokines, were particularly effectively protected against gamma irradiation. Ginsan treatment also clearly enhanced the functional activity of T cells. Therefore, Ginsan should be considered as a good candidate for improvement of gamma radiation's immunosuppressive effects.

# **ACKNOWLEDGEMENT**

This work was supported by a grant from the "National R&D program" of the Ministry of Science and Technology, Republic of Korea.

## **REFERENCES**

- Ballas, Z. K., Rasmussen, W., and Van Otegham, J. K., Lymphokine-activated killer (LAK). I1. Delineation of distinct murine LAK-precursor subpopulation. *J. ImmunoL,* 138, 1647-1652 (1987).
- Chen, Y. M, Ting, C. C., Peng, J. W., Yang, W. K., Yang, K. Y., Tsai, C. M., and Perng, R. P., Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs. interleukin-2. *J. Interferon Cytokine Res.,* 20(1 ), 31-39 (2000).
- Doherty, P. C., Grosveld, G. C., and Ihle, J. N., Requirement for Stat4 in interleukin-12-mediated response of natural killer and T cells. *Nature,* 382, 171-174 (1996).
- Galdiero, M., Cipollaro del'Ero, G., Folgore, A., Cappello, M., Giobbe, A., and Sasso, F. S., Effects of irradiation doses on alteration in cytokine release by monocytes and lymphocytes. *J. Med.,* 25, 23-40 (1994).
- Gao, Q. P., Kiyohara, H., Cyong, J., and Yamada, H., Chemical properties and anticomplementary activities of heteroglycans from the leaves of panax ginseng. *Planta Med.,* 57, 132-136 (1991).
- Grimm, E. A., Mazumder, A., Zhang, Z., and Rosenberg, S. A., Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. *J. Exp. Med.,* 155, 1823-1841 (1982).
- Han, S. K., Song, J. Y., Yun, Y. S., and Yi, S. Y., Gamma irradiation reduced IFN-gamma expression, STAT-1 signal, and cell-mediated immunity. *J. Biochem. Mol. BioL,* 35(6), 583-589 (2002).
- Khan, I. A. and Casciotti, L., IL-15 prolongs the duration of CD8+ T cell-mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii. J. *ImmunoL,* 163(8), 4503-4509 (1999).
- Kim, S. I., Kang, K. S, and Lee, Y. H., Panaxyne epoxide, a new cytotoxic polyne from panax ginseng root against L1210 cells. *Arch. Pharm. Res.,* 12, 48-51 (1989).

Kim, Y. S., Kang, K. S., and Kim, S. I., Study on antitumor and

immunomodulating activities of polysaccharides fraction from parax ginsans: Comparison of effect of neutral and acidic polysaccharide fraction. *Arch. Pharm. Res.,* 13, 330-337 (1990).

- Lee, Y. S., Jung, I. S., Lee, I. R., Kim, K. W., Hong, W. S., and Yun, Y. S., Activation of Multiple Effecter pathway of immune system by the antineoplastic immunostimulator acidic polysaccharide ginsan isolated from panax ginseng. *Anticancer Res.,* 17, 323-331 (1997).
- Maeda, Y. Y., Watanabe, S. T., Chilara, G., and Rokutanda, M., T-cell mediated vascular dilation and hemorrhage induced by antitumor polysaccharide. *Intl. J. Immunopharmacol,* 6, 493- 501 (1984).
- Mule, J. J., Shu, S., and Rosenberg, S., The antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 *in vivo. J. Immunol.,* 135, 646-652 (1985).
- Murren, J. R. and Buzaid, A. C., The role of interferons in the treatment of malignant neoplasms. *Yale J. BioL Med.,* 62, 271-290 (1989).
- Ochoa, A. C., Gromo, G., Alter, B. J., Sondel, P. M., and Bach, E I1., Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, blL-1, interferon-g and -b. J. *immunoL,*  138, 2728-2733 (1987).
- Oldham, R. K., Biological response modifiers program and chemotheraphy. *Int. J. Tissue React.,* 4, 173-188 (1982).
- Pharmacognosy, Korea association of pharmacognosy, hakchang press (1995).
- Rosenberg, S., Lotze, M., Muul, L., Leitman, S., Chang, A., Ettinghausen, S., Matury, Y., Skibber, J., Shilon, E., Vetto, J., Seipp, C., Simpson, C., and Reichert, C., Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N. Engl. J. Med.,* 313, 1485-1492 (1985).
- Shuat, K., Horvath, C. M., Huang, L. H. T., Qureshi, S. A., Cowburn, D., and Darnell, J. E., Interferon activation of transcription factor Stat1 involves dimerization through SH2-Phosphotyrosyl peptide interactions. *Cell,* 76, 821-828 (1994).
- Singh, V. K., George, C. X., Singh, N., Agarwal, S. S., and Gupta, B. M., Combined treatment of mice with Panax ginseng extract and interferon inducer. *Planta Med.,* 47, 234- 236 (1983).
- Smalley, R. V. and Oldham, R. K., Phase I trials of biological response modifiers. *Drugs Exptl. Clin. Res.,* 12, 31-39 (1986).
- Song, J. Y., Han, S. K., Bae, K. G., Lim, D. S., Son, S. J., Jung, I. S., Yi, S. I., and Yun, Y. S., Radioprotective effects of Ginsan, an immunomodulator. *Radiat. Res.,* 159(6), 768-774 (2003).
- Song, J. Y., Han, S. K., Son, E. H., Pyo, S. N., Yun, Y. S., Yi, S. Y., Induction of secretory and tumoricidal activities in peritoneal macrophages by Ginsan. *Int. Immunopharmacol.,*  2(7), 857-865 (2002).
- Sredni, B., Caspi, R.R., Klein, A., Kalechman, Y., Danziger, Y., BenYa'akov, M., Tamari, T., Shalit, E, and Albeck, M., A new immunomodulating compound (AS101) with potential therapeutic application. *Nature,* 330, 173-176 (1987).
- Strander, H., Clinical effects of interferon therapy with special emphasis on antitumor efficacy. *Acta Oncologica,* 28, 355- 362 (1989).
- Talmadge, J. E. and Herberman, R. B., The preclinical screening laboratory: Evaluation of immunomodulatory and therapeutic properties of biological response modifiers. *Cancer Treatment Reports,* 70, 171-182 (1986).
- Talmadge, J. E., Fidler, I. J., and Oldham, R. K., The NCI preclinical screen of biological response modifiers. *Behring Inst. Mitt.,* 74, 189-194 (1984).
- Uchida and Micksche, M., *In vitro augmentation* of natural killing activity by OK-432. *Int. J. Immunopharmac.,* 3, 365-375 (1981).
- Wiltrout, R. H. and Hornung, R. L., natural products as

antitumor agents: direct versus indirect mechanisms of activity of flavonoids. *J. NatI.Cancer Institute,* 80, 220-222 (1988).

- Wimer, B. M., The ideal biological response modifier. *MoI. Biother.,* 1,311-317 (1989).
- Yanagawa, E., Yasumoto, K., Ohta, M., Nomoto, K., Azuma, I., and Yamamura, Y., Comparative study on antitumor effect of cell-wall skeleton of Mycobacterium bovis BCG and Nocardia rubra, with reference to T-cell dependency and independency. *JPN. J. Cancer Res.*, 70, 141-146 (1979).
- Yang, J. C., Mule, J. J., and Rosenberg, S., Murine lymphokineactivated killer (LAK) cells: phenotypic characterization of the precursors and effector cells. *J. Immunol.,* 137, 715-722 (1986).
- Yun, Y.-S., Lee, Y.-S., Jo, S.-K., and Jung, I.-S., Inhibition of autochthonous tumor by ethanol insoluble fraction from panax ginseng as an immunostimulator. *Planta medica,* 59, 521-524 (1993).